Medical Oncology

DLBCL

Questions discussed in this category

What is the best treatment approach to a patient with HGBCL with FISH translocation of BCL-6 and c-Myc given new classification of this entity?

2 Answers available

Is there any role for radiation in the treatment of stage II nasopharyngeal DLBCL involving bilateral nasopharynx and unilateral cervical nodal involvement but without bony or nerve involvement?

2 Answers available

How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?

At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...

2 Answers available

What chemotherapy regimen would you offer to a patient with DLBCL who was originally diagnosed and treated (R-CHOP) 15 years ago, now with a 2nd primary/late recurrence of DLBCL?

1 Answer available

For patients with primary CNS lymphoma and less than a CR to chemotherapy, in what situation would you consider partial or focal radiation?

1 Answer available

How would one approach concomitant diffuse large B cell lymphoma and fibrotic phase myelofibrosis?

1 Answer available

What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?

1 Answer available

How are you deciding between available third line therapies for post-transplant relapsed DLBCL?

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

1 Answer available

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

1 Answer available

How do you prepare patients with DLBCL on the potential need for cellular therapies after progression on first line regimens?

When is this discussed? What are the common/less common toxicities you advise patients on? Are there best practices for coordination with referring on...

3 Answers available